Asea A, Ara G, Teicher B A, Stevenson M A, Calderwood S K
Department of Radiation Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Int J Hyperthermia. 2001 Jul-Aug;17(4):347-56. doi: 10.1080/02656730110053146.
Tumour hyperthermia, although potentially a powerful therapeutic agent and radiation sensitizer, is hindered by a number of considerations including inhomogeneous heating of deep seated tumours due to energy deposition and perfusion issues. One solution is to design hyperthermia sensitizers to amplify the effects of hyperthermia, particularly at cold spots within the tumour undergoing treatment. This study examined the use of Quercetin, a flavonoid drug shown previously to antagonize the expression of HSP72 and induce apoptosis as a sensitizer of prostate cancer growth in vivo. Quercetin dose-dependently suppressed PC-3 tumour growth in vitro and in vivo. When combined in a treatment protocol with hyperthermia, quercetin drastically inhibited tumour growth and potently amplified the effects of hyperthermia on two prostate tumour types, PC-3 and DU-145 in vivo. These experiments, thus, suggest the use of Quercetin as a hyperthermia sensitizer in the treatment of prostate carcinoma.
肿瘤热疗虽然可能是一种强大的治疗剂和辐射增敏剂，但受到多种因素的限制，包括由于能量沉积和灌注问题导致深部肿瘤加热不均匀。一种解决方案是设计热疗增敏剂来增强热疗效果，特别是在接受治疗的肿瘤内的冷点处。本研究考察了槲皮素的应用，槲皮素是一种黄酮类药物，先前已证明其可拮抗HSP72的表达并诱导细胞凋亡，作为体内前列腺癌生长的增敏剂。槲皮素在体外和体内均呈剂量依赖性抑制PC-3肿瘤生长。当与热疗联合应用于治疗方案时，槲皮素在体内显著抑制肿瘤生长，并有力地增强了热疗对两种前列腺肿瘤类型PC-3和DU-145的作用。因此，这些实验表明槲皮素可作为热疗增敏剂用于前列腺癌的治疗。
